NFL Biosciences: Invest Securities raises its target

(CercleFinance.com) - Invest Securities confirms its Buy rating on NFL Biosciences shares, and raises its target price from 5.
5 to 8.8 euros.

The analyst reports that CESTO-2 results, released this morning, are "globally satisfactory" and will enable the company to validate a move into Phase III.

"Management now anticipates a full scientific publication after the summer, while continuing to prepare Phase III in order to maximize its chances of signing a licensing agreement, which we expect in 2025 in the US and Europe, potentially before running out of cash (Q2 25)", the broker points out.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.